prt-2607
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01652937)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase SYKINHIBITOR
SYK inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545138 ↗
Also known as
- 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide
- biib057
- biib057
- biib-057
- biib-057
- p505-15
- p505-15
- p505-15
- prt062607
- prt-062607
- prt-062607
- prt-2607
- prt-2607
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01652937 | Phase 2 | Aug 1, 2012 | Biogen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1